Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: A cross-sectional study

BMJ Open

Volumn 6, Issue 5, 2016, Pages

  Qureshi, Sheharyar A ^a   Burch, Nicola ^a   Druce, Maralyn ^b   Hattersley, John G ^a   Khan, Saboor ^a   Gopalakrishnan, Kishore ^a   Darby, Catherine ^a   Wong, John L H ^a   Davies, Louise ^a   Fletcher, Simon ^a   Shatwell, William ^a   Sothi, Sharmila ^a   Randeva, Harpal S ^a,c,d   Dimitriadis, Georgios K ^a,c   Weickert, Martin O ^a,c,d  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d Faculty of Engineering and Computing   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CREATININE; ELASTASE; SOMATOSTATIN DERIVATIVE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HORMONE; SOMATOSTATIN;

ABDOMINAL SURGERY; ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISTANT METASTASIS; FEMALE; FUNCTIONAL STATUS; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HEMICOLECTOMY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MALNUTRITION UNIVERSAL SCREENING TOOL; MIDDLE AGED; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; PRIMARY TUMOR; RADIOIMMUNOASSAY; SCREENING; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; ENGLAND; EPIDEMIOLOGY; GASTROINTESTINAL TUMOR; METABOLISM; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; GASTROINTESTINAL NEOPLASMS; HORMONES; HUMANS; MALE; MALNUTRITION; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84971273091     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010765     Document Type: Article

References (34)

1. Barker LA, Gout BS, Crowe TC. Hospital malnutrition: prevalence, identification and impact on patients and the healthcare system. Int J Environ Res Public Health 2011;8:514-27.
2. 32 Ncg. Nutrition support in adults: Oral nutrition support, enteral tube feeding and parenteral nutrition. 2006. http://guidance.nice.org.uk/cg32(accessed 3 Dec 2015).
3. de Ulibarri Perez JI, Picon Cesar MJ, Garcia Benavent E, et al. Early detection and control of hospital malnutrition. Nutr Hosp 2002;17:139-46.
4. Stratton RJ, Hackston A, Longmore D, et al. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the 'malnutrition universal screening tool' ('MUST') for adults. Br J Nutr 2004;92:799-808.
5. Isenring E, Elia M. Which screening method is appropriate for older cancer patients at risk for malnutrition? Nutrition 2015;31:594-7.
6. Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010;39:713-34.
7. Feldman JM, Plonk JW. Gastrointestinal and metabolic function in patients with the carcinoid syndrome. Am J Med Sci 1977;273:43-54.
8. Oosterbosch L, von der Ohe M, Valdovinos MA, et al. Effects of serotonin on rat ileocolonic transit and fluid transfer in vivo: possible mechanisms of action. Gut 1993;34:794-8.
9. Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer 2013;20:187-96.
10. Aspestrand F, Pollard L. Carcinoid infiltration and fibroplastic changes of the mesentery as a cause of malabsorption. Radiologe 1986;26:79-81.
11. Nash DT, Brin M. Malabsorption in malignant carcinoid with normal 5 Hiaa. N Y State J Med 1964;64:1128-31.
12. Evensen D, Hanssen KF, Berstad A. The effect on intestinal calcium absorption of somatostatin in man. Scand J Gastroenterol 1978;13:449-51.
13. Krejs GJ, Browne R, Raskin P. Effect of intravenous somatostatin on jejunal absorption of glucose, amino acids, water, and electrolytes. Gastroenterology 1980;78:26-31.
14. Corinaldesi R, Stanghellini V, Barbara G, et al. Clinical approach to diarrhea. Intern Emerg Med 2012;7(Suppl 3):S255-62.
15. BAPEN. Introducing "MUST". 2015. http://www.bapen.org.uk/screening-for-malnutrition/must/introducing-must(accessed 03 Dec 2015).
16. (MAG) MAG. MAG screening tool and guidelines set to combat malnutrition. 2001. http://www.guidelinesinpractice.co.uk/feb-01-elia-malnutrition-feb01#.Vg1JSTZdFMt (accessed 26 Feb 2016).
17. Boleo-Tomé C, Monteiro-Grillo I, Camilo M, et al. Validation of the Malnutrition Universal Screening Tool (MUST) in cancer. Br J Nutr 2012;108:343-8.
18. Maasberg S, Knappe-Drzikova B, Vonderbeck D, et al. Malnutrition predicts clinical outcome in patients with neuroendocrine neoplasias. Neuroendocrinology 2015. [epub ahead of print 8 Dec 2015].
19. Harris D, Haboubi N. Malnutrition screening in the elderly population. J R Soc Med 2005;98:411-14.
20. Vinik A, Feliberti E, Perry RR. Carcinoid tumors. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al, eds. Endotext. South Dartmouth, MA: 2014. http://www.ncbi.nlm.nih.gov/pubmed/25905385
21. Boden G, Sivitz MC, Owen OE, et al. Somatostatin suppresses secretin and pancreatic exocrine secretion. Science 1975;190:163-5.
22. Hopman WP, van Liessum PA, Pieters GF, et al. Pancreatic exocrine and gallbladder function during long-term treatment with octreotide (SMS 201-995). Digestion 1990;45(Suppl 1):72-6.
23. Ho PJ, Boyajy LD, Greenstein E, et al. Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly. Dig Dis Sci 1993;38:309-15.
24. Lamrani A, Vidon N, Sogni P, et al. Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans. Br J Clin Pharmacol 1997;43:65-70.
25. Schlegel W, Raptis S, Harvey RF, et al. Inhibition of cholecystokinin-pancreozymin release by somatostatin. Lancet 1977;2:166-8.
26. Chisholm C, Greenberg GR. Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. Am J Physiol Endocrinol Metab 2002;283:E311-17.
27. Magnusson I, Einarsson K, Angelin B, et al. Effects of somatostatin on hepatic bile formation. Gastroenterology 1989;96:206-12.
28. Hussaini SH, Pereira SP, Veysey MJ, et al. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Gut 1996;38:775-83.
29. Vinik A, Feliberti E, Perry RR. Somatostatinoma. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al, eds. Endotext. South Dartmouth, MA: 2013. http://www.ncbi.nlm.nih.gov/pubmed/25905263
30. Fiebrich HB, Van Den Berg G, Kema IP, et al. Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue. Aliment Pharmacol Ther 2010;32:1398-404.
31. Lembcke B, Creutzfeldt W, Schleser S, et al. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987;36:108-24.
32. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371:224-33.
33. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
34. Paccagnella A, Morassutti I, Rosti G. Nutritional intervention for improving treatment tolerance in cancer patients. Curr Opin Oncol 2011;23:322-30.